Par acquires rights to generic version of Seroquel XR
WOODCLIFF LAKE, N.J. – Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.
Par said it bought marketing and distribution rights to generic quetiapine fumarate extended-release tablets from Handa Pharmaceuticals, acquiring Handa’s regulatory approval application for the drug. The deal gives Par the right to market, sell and distribute the drug after it receives approval from the Food and Drug Administration and receive a share of the profits. Par itself has a license to market the drug starting in November 2016, under a deal with AstraZeneca.
The drug is a generic version of AstraZeneca’s Seroquel XR, and Handa considers itself the first company to file a complete application for the generic drug in the 50-mg, 150-mg, 200-mg and 300-mg strengths. If it is, then the drug will have 180 days in which to compete directly with AstraZeneca’s product, according to generic drug regulations.
Seroquel XR has annual sales of about $808 million, according to IMS Health.
CVS/pharmacy helping customers prepare for Hurricane Sandy
WOONSOCKET, R.I. — As Hurricane Sandy makes landfall today, CVS/pharmacy has announced that, while complying with any mandatory evacuation orders given by local officials, it is keeping its stores in affected areas open for as long as possible. CVS is also deploying generators throughout affected markets as needed to provide power to key store locations in the event of power outages.
CVS/pharmacy is also keeping stores stocked with storm preparedness items such as water, batteries, flashlights and other products to help in an emergency. Any stores that close due to the storm will reopen as soon as safely possible.
The company is also prepared to assist with storm recovery efforts in its communities and will keep in close contact with the American Red Cross to offer support in affected areas as needed once the storm passes.
Customers can access their prescription information at the Pharmacy section of CVS.com, with resources such as My Pharmacy, where patients can easily view all of their prescriptions and manage refills, and a Drug Information Center where they can ensure medications can be taken together and view descriptive images of each prescribed pill, the pharmacy retailer stated. Prescription management services are also available at CVS/pharmacy’s mobile website, m.cvs.com, and through CVS/pharmacy’s iPhone and Android mobile apps.
When preparing for a hurricane or other serious weather event, CVS/pharmacy is offering customers the following tips:
- Create a plan for evacuating and finding a safe destination;
- Keep a written record of your current prescriptions with you at all times, or create an online record at CVS.com. This is especially important if you take multiple prescriptions;
- In the event of an emergency when you are away from home, find a pharmacy nearby to fill necessary prescriptions. CVS/pharmacy can fill its customers’ prescriptions at any of its 7,400 locations nationwide; and
- Create an emergency kit and make sure you have all essentials in case of power outages. CVS/pharmacy has the necessities for a hurricane kit including bottled water, masking tape and batteries.
Watson launches generic version of Actos
PARSIPPANY, N.J. – The Food and Drug Administration has approved a Type 2 diabetes drug made by Watson Pharmaceuticals, the company said, following a federal court’s order for the agency to approve the drug.
Watson announced the launch of pioglitazone hydrochloride tablets in the 15-mg, 30-mg and 45-mg strengths. The drug is a generic version of Takeda’s Actos, branded and generic versions of which had sales of about $2.7 billion during the 12-month period ended in August, according to IMS Health.
The launch follows a decision by the U.S. District Court for the District of Columbia to order the FDA to allow the launch. Watson filed suit against the FDA in August 2012, alleging that an agency decision to deny Watson’s claim to shared exclusivity with Mylan in marketing a generic version of Actos would improperly delay its launch of the drug. Mylan itself had attempted to intervene to stop the launch of the drug by filing a motion in the court to stay the court’s order.